1. Beck, W. T. & Danks, M. K. (1991). Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Sem Cancer Biol 2: 235–244.
2. Boritzki, T. J., Wolfard, T. S., Besserer, J. A., Jackson, R. C. & Fry, D. W. (1988). Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37: 4063–4068.
3. Bouma, P. & Uges, D. R. A. (1980). Preparation of highly efficient columns for high-performance liquid chromatography. In: The Serum Concentration of Drugs, International Congress Series 501, Merkus FWHM (ed), pp 278–280, Excerpta Medica: Amsterdam
4. Clinical Brochure Fostriecin, (1991). Bethesda, MD, USA National Cancer Institute
5. Cummings, J. & Smyth, J. F. (1993). DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4: 533–543.